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a b s t r a c t
Green tea is rich in polyphenol ﬂavonoids including catechins. Epigallocatechin 3-gallate (EGCG) is the
most abundant and potent green tea catechin. EGCG has been extensively studied for its beneﬁcial health
effects as a nutriceutical agent. Based upon its chemical structure, EGCG is often classiﬁed as an
antioxidant. However, treatment of cells with EGCG results in production of hydrogen peroxide and
hydroxyl radicals in the presence of Fe (III). Thus, EGCG functions as a pro-oxidant in some cellular
contexts. Recent investigations have revealed many other direct actions of EGCG that are independent
from anti-oxidative mechanisms. In this review, we discuss these novel molecular mechanisms of action
for EGCG. In particular, EGCG directly interacts with proteins and phospholipids in the plasma membrane
and regulates signal transduction pathways, transcription factors, DNA methylation, mitochondrial
function, and autophagy to exert many of its beneﬁcial biological actions.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
Polyphenols may have therapeutic health effects for a variety of
chronic pathological conditions including cancer, neurodegenera-
tive diseases, diabetes, and cardiovascular diseases [16,51,106].
Many polyphenols are derived from natural food products. Thus,
they are often considered safer and more easily integrated into
lifestyle changes than conventional pharmaceutical drugs.
Recently, speciﬁc molecular targets for various polyphenols have
been discovered. Therefore, scientiﬁc interest in polyphenols as
therapeutic agents is rapidly increasing. However, many studies
often report biological effects of food polyphenols are observed
without elucidating the underlying molecular, cellular, and phy-
siological mechanisms. Obstacles to deﬁning mechanistic studies
in this ﬁeld may include non-speciﬁc effects due to polyphenols
with pleiotropic activities, and complex mechanisms of action.
Despite difﬁculties in deﬁning speciﬁc mechanisms, recent work
has shed light on more detailed molecular mechanisms underlying
bioactive actions of polyphenols. Many polyphenols share bene-
ﬁcial effects against a broad range of pathologies, including cancer,
inﬂammation, diabetes, and cardiovascular diseases. However,
individual polyphenols have distinct speciﬁc molecular targets in
various tissues with different efﬁcacies and bioavailabilities.
Dietary sources of polyphenols have received a great deal of
attention. In particular the polyphenolic components in different
tea preparations have been examined in detail. Tea is the second
most frequently consumed beverage after water. Tea polyphenols
have received considerable public attention due to the positive
association between tea consumption and beneﬁcial health effects
[56]. Epidemiological studies show correlations between tea con-
sumption and decreased risk of cardiometabolic disorders and
mortality in a dose-dependent fashion [56]. Green tea extract
contains a number of catechins, including epigallocatechin-gallate
(EGCG), epigallocatechin (EGC), epicatechin-gallate (ECG), and
epicatechin (EC). The proﬁles of catechins in human plasma and
urine after tea consumption have been analyzed [29,61,112].
Although the absorption, excretion, and modiﬁcation of catechins
may affect the bioavailabilities and bioactive potencies, structural
characteristics seems to play important roles in differential
bioactivities. It has been proposed that the galloyl moiety of tea
catechins may play the critical roles in speciﬁc activities of tea
catechins, especially in lipid lowering effect [39,40]. Furthermore,
the two catechins with galloyl moiety (EGCG and ECG) have the
most potent biological activities as listed in Table 1. The most
abundant green tea polyphenol, epigallocatechin 3-gallate (EGCG)
may be responsible for many of the beneﬁcial effects of green tea
in clinical and animal studies as well as in cell culture studies
[7,14,47–49,87,101]. One potential mechanism for beneﬁcial
health effects of EGCG may be attributable to its anti-oxidative
function [9]. However, more recent ﬁndings suggest many addi-
tional mechanisms of action for EGCG including interactions with
plasma membrane proteins, activation of second messengers and
signal transduction pathways, modulation of metabolic enzymes,
and autophagy [47,49,55,110,111,124]. Furthermore, the biological
actions of EGCG are concentration-dependent. Bioavailability stu-
dies after tea consumption demonstrate levels of EGCG in human
plasma in the low μM range [60]. Circulating levels of EGCG reach
about 10 μM in animal studies after oral intake of pure EGCG [57].
In this review, the concentration-dependent biological actions of
EGCG (low deﬁned as r10 mM and high deﬁned as 410 μM) and
recent progress in elucidation of speciﬁc molecular mechanisms of
action are discussed (Table 2).
Pro-oxidant or anti-oxidant?
Oxidant properties of polyphenols may be both anti-oxidant
and/or pro-oxidant based upon the structure of the particular
polyphenol and the cellular redox context that may include
increased levels of oxidant scavenging proteins or decreased levels
of oxidized proteins and lipids [11,76,122]. Thus, some studies
claim EGCG is an anti-oxidant [7,44,83,118]. For example, mito-
chondrial function is improved by anti-oxidative action of EGCG
[72]. Moreover, EGCG ameliorates lipid infusion-mediated insulin
resistance, which is associated with increased expression of anti-
oxidant enzymes including superoxide dismutase (SOD) and
glutathione peroxidase by EGCG in vivo [66]. However, these
reports are associative and do not directly demonstrate that a
Table 1
Relative biological potency of green tea polyphenols.
Biological actions EGCG ECG EGC EC Ref.
Inhibition of histamine release Strong Moderate Moderate No effect [70]
Inhibition of leukotriene B4 release Strong Moderate Moderate No effect [70]
Angiogenesis Strong Strong Weak Weak [53]
RyR1 activation EGCG4 ECG4 EGC4 EC [27]
Cytotoxicity in oral cavity EGCG4 ECG4 EGC4 EC [5]
FAS inhibition EGCGo ECG [105]
SIRT1 activation 1.75 fold 1.85 fold [19]
Na/H exchanger inhibition EGCGo ECGo EGCo EC [92]
Table 2
Effects of EGCG treatment on various cellular responses.
Cellular function Cell types Con. EGCG (μM) Mechanism Reference
Glucose uptake 3T3-L1 o5 Anti-oxidant [118]
Adipocyte differentiation 3T3-L1 5–10 Up-regulate Adipogenic Genes [98]
Inhibition of gluconeogenesis Hepatocyte o1 CaMKKβ/AMPK pro-oxidant [15]
Autophagy Endothelial cells 10 Ca2þ þ/CaMKKβ [47]
Autophagy/Anti-tumor (cell death) Cancer 450 Pro-oxidant [63,99,124]
Transformation Cancer 20 AP-1 inhibition [21]
Protection HaCaT 420 Pro-oxidant [22]
Anti-proliferation Cancer 420 Pro-oxidant [36,64]
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decrease in oxidative stress by EGCG per se is the direct mechan-
ism preventing lipid-induced insulin resistance. On the other
hand, other reports suggest that green tea extract and EGCG exert
pro-oxidant actions [23,36,64,97,121]. EGCG auto-oxidizes, and
produces hydrogen peroxide in cell culture media with and with-
out cells. Addition of SOD and catalase abolishes some cellular
actions of EGCG by inhibiting the auto-oxidation and dimerization
of EGCG [64]. EGCG works in two ways to promote cytotoxicity in
anti-tumor activity; one is directly by producing hydrogen per-
oxide with its pyrogallol moiety, and the other is reducing Fe (III)
to Fe (II) which triggers the Fenton reaction to create more potent
reactive oxygen species (ROS) such as hydroxyl radicals [77,78].
The combination of hydroxyl radicals and hydrogen peroxide
contributes to the cytotoxic effects of EGCG at high mM concentra-
tions (450 μM). Another study has shown that N-acetyl cysteine
(NAC) is able to protect from hydrogen peroxide-induced cyto-
toxicity but not EGCG-induced cell death. Thus, the cytotoxic effect
of EGCG in tumor cells is not mimicked by hydrogen peroxide
alone [117]. This suggests that EGCG has tumor-speciﬁc mechan-
isms for mitochondrial damage other than production of hydrogen
peroxide. However, these results are based upon cell culture
studies using 450 μM EGCG (50 μM EGCG generates about
1 μM hydrogen peroxide in Jurkat cells) [77]. In fact, more modest
nM and biologically realistic concentrations (1–2 μM up to 10 μM)
of EGCG produce lower levels of intracellular reactive oxygen
species that stimulate multiple signal transduction pathways to
promote cellular protective mechanisms [15,22]. This suggests that
EGCG-mediated production of reactive oxygen species contributes
to the beneﬁcial biological actions of EGCG. It is possible that
different amount of anti-oxidants, including glutathione, thiore-
doxin, catalase and SOD in various tissues and serum components
in animal models may underlie discrepancies in the activities of
EGCG under in vitro and in vivo conditions. Moreover, expression
levels of modifying enzymes and their stability may also be factors
determining bioavailability of EGCG. EGCG is converted to dimer
and multimer, and modiﬁed to glucuronated and/or methylated
forms. Since many cellular actions of EGCG are acute and occur
within minutes, it is likely that EGCG has direct cellular actions
that are independent of its metabolites. However, the various
metabolites of EGCG may also have some bioactivity, particularly
with respect to chronic actions of green tea extracts. Thus, distinct
actions and roles of these derivatives may also contribute to
pleiotropic biological effects of EGCG [107]. Although it has not
been proven that oxidation of EGCG occurs in vivo, all of the forms,
including intact, oxidized or modiﬁed EGCG are potentially bioac-
tive substances. Therefore, the combination of direct and indirect
effects of EGCG may create synergistic or additive mechanisms for
various actions of green tea.
Cell surface receptor
One important mechanism frequently overlooked in consider-
ing the biological effects of polyphenols is their potential
interaction with receptors capable of initiating cell signaling.
Interestingly, when EGCG is incubated with cells, 75% of radio-
actively labeled EGCG is found in the cytosolic compartment while
some radioactivity is found in the membrane fraction [34]. This
suggests that EGCG directly binds to membrane components,
including proteins and lipids. In fact, EGCG inhibits PDGFR-BB-
stimulated signal transduction pathway in vascular smooth muscle
cells by direct binding to PDGFR-BB thereby causing inhibition of
PDGF-stimulated restenosis [1,95,114]. Moreover, EGCG regulates
activities of cell surface growth factor receptors, especially recep-
tor tyrosine kinases (RTK), including epidermal growth factor
receptor (EGFR), vascular endothelial growth factor receptor
(VEGFR), insulin-like growth factor receptor (IGFR), and the insulin
receptor (InsR) (Table 3). [1,53,67,93,96,102,113]. Most RTKs are
involved in cell proliferation, survival and angiogenesis. In parti-
cular, InsR is important for regulation of metabolism and cell
survival. It is notable that EGCG inhibits activities of EGFR, VEGFR,
and IGFR. By contrast, EGCG mimics or augments InsR signaling
[113]. One mechanism proposed for activation of InsR is that EGCG
inhibits tyrosine phosphatases through a redox mechanism that
results in increased and sustained tyrosine phosphorylation of
InsR [113] by increasing the level of hydrogen peroxide. Thus,
inhibitory actions of EGCG on proliferation may be speciﬁc to
abnormally proliferating or cancer cells, but not to normal cells. In
fact, by using surface plasmon resonance technique, Tachibana
et al. discovered that EGCG, but not other tea catechins, directly
binds to the laminin receptor (67LR) (Kdnanomolar) [81]. The
binding site in 67LR is located within the peptide LR161-170 and
the two basic amino acids K(166) and H(169) are critical for the
binding of EGCG [28]. The expression of 67LR is elevated in cancer
cells but not in normal cells [71]. This suggests that EGCG may
speciﬁcally target cancer cells in some contexts. More recently,
Kumazoe et al. suggested a mechanism for EGCG-induced apop-
tosis of cancer cells through 67LR that may provide a potential
therapeutic strategy using inhibitors of phosphodiesterase 5
(PDE5) (Fig. 1) [116]. Another role of EGCG-stimulated 67LR is to
mediate anti-inﬂammatory actions. Treatment with EGCG reduces
expression of toll–like receptor 4 (TLR4) and increases expression
of tollip, a negative regulator of TLRs, through a 67LR-dependent
mechanism [33]. Because TLR2 and TLR4 are involved in innate
immunity in response to bacterial infection, this activity of EGCG
inhibits lipopolysaccharide-stimulated pro-inﬂammatory responses
in macrophages [33]. Identifying the detailed mechanisms for
67LR-mediated reduction of TLR4 and increased tollip expression
will provide more detailed mechanisms for anti-inﬂammatory
actions of EGCG. Growing evidence suggests that 67LR plays
important roles in biological actions of EGCG (Fig. 2). Despite the
importance of 67LR in the activities of EGCG, detailed downstream
signaling pathways for 67LR are yet to be elucidated.
Intracellular signaling pathways
In cell culture, the majority of [3H]–EGCG is found in the
cytosolic fraction [34]. This suggests that biological actions of
EGCG may occur through EGCG metabolites or interaction with
intracellular molecules. As mentioned above, EGCG produces low
level reactive oxygen species, including hydrogen peroxide that
may act as a second messenger for downstream signaling path-
ways [23,36,64,97,121]. This action may be mediated by direct
chemical reactions of EGCG with compounds at the cell surface.
However, additional unknown receptor-mediated signaling path-
ways cannot be excluded. EGCG also increases other intracellular
second messengers including Ca2þ , cAMP, and cGMP.
Table 3
Effects of EGCG on receptor tyrosine kinases.
Biological
actions
Signaling
molecule
Conc. of EGCG
(μM)
Inhibition/
Activation
Reference
Atherosclerosis PDGF-BB 5–100 Inhibition [1]
Angiogenesis VEGFR 1.56–100 Inhibition [53]
Cancer EGFR 410 Inhibition [67]
Angiogenesis VEGFR 0.5–10 Inhibition [93]
Cancer EGFR 30–50 Inhibition [96]
Gluconeogenesis InsR 5–50 Activation [113]
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Calcium
EGCG elevates cytosolic Ca2þ levels in excitable and non-
excitable cells [13,47,50]. Elevation of Ca2þ is achieved after
stimulation with nanomolar concentrations of EGCG and ECG,
but not by EGC or EC. This increases the sensitivity of the
ryanodine receptor (RyR1) in response to extracellular Ca2þ
inward current or electrical stimulation without changing basal
cytosolic Ca2þ [27]. This effect is independent of sarcoplasmic/
endoplasmic reticulum Ca2þ-ATPase (SERCA) activity at concen-
trations of EGCG up to 2 μM. However, 10 μM EGCG elevates
cytosolic Ca2þ without Ca2þ challenge or electrical stimulation.
This is inhibited by depletion of endoplasmic reticulum Ca2þ stores
by treatment with cyclopiazonic acid in bovine aortic endothelial
cells [47]. This suggests that concentrations of EGCG410 μM
elevate cytosolic Ca2þ by inhibition of SERCA [43,103]. This elevated
cytosolic Ca2þ affects activities of various Ca2þ requiring enzymes
including calmodulin (CaM)-dependent protein kinase II and
CaMKKβ [47,50]. CaMKKβ is an upstream regulator for AMP-
dependent kinase (AMPK), an energy sensing enzyme that plays
crucial roles in energy metabolism and cardiovascular functions
[79,94,108]. EGCG-stimulated elevation of cytosolic calcium con-
tributes to NO production by binding to calmodulin in the heart and
vascular endothelium [32,35,73]. These actions of EGCG are closely
related to beneﬁcial cardiovascular actions of EGCG.
Cyclic-nucleotides (cAMP/cGMP)
EGCG treatment increases cAMP in endothelial cells and plate-
lets that participate in phosphorylation of eNOS and vasodilator-
stimulated phosphoprotein (VASP) [68,82]. However, this seems to
be a cell type-speciﬁc response because elevation of intracellular
Fig. 1. EGCG-activated eNOS pathways that improve cardiovascular function and anti-cancer effect in the presence of PDE5 inhibitor. EGCG elevates cGMP levels through a
speciﬁc receptor 67LR that stimulates the Akt/eNOS pathway. This pathway leads to vasodilation which contributes to improvement of cardiovascular function. In cancer
cells, inhibition of PDE5 by treatment with Vardenaﬁl leads to sustained elevations of cGMP levels. This elevated cGMP activates PKCδ/acidic sphingomyelinase (ASM) that
contributes to apoptosis.
Fig. 2. The roles of 67LR as a speciﬁc receptor for EGCG. EGCG has multiple biological actions mediated through 67LR by enhancing (red) and inhibiting (blue) speciﬁc
pathways.
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cAMP by EGCG is not observed in other cell types. Although the
detailed molecular mechanism for elevation of cAMP is not
known, elevation of cAMP may be achieved through activation of
adenylate cyclase, but not through inhibition of phosphodiesterase
4 (PDE4) [82]. This elevated cAMP stimulates protein kinase A that
contributes to various biological events [24,68]. By contrast, EGCG
stimulates production of NO through a 67LR-mediated mechanism
leading to apoptosis in cancer cells and acute myeloid leukemia
cells [54,55,119]. This effect is potentiated by the PDE5 inhibitor
Vardenaﬁl in cancer cells but not in normal cells. Thus, prolonged
elevation of cGMP by EGCG and Vardenaﬁl leads to potentiated
cell death. Interestingly, cancer cells express abnormally high
levels of 67LR and PDE5. This may aid in cancer-speciﬁc targeted
treatment. This novel mechanism provides a combinatorial ther-
apeutic strategy to treat cancer patients with EGCG and PDE5
inhibitors [55]. EGCG also stimulates vasorelaxation by increasing
both cAMP and cGMP in rat aorta [3]. Thus, EGCG may stimulate
production of cyclic nucleotides that may be one of the important
mechanisms underlying beneﬁcial biological actions of EGCG in
metabolic and cardiovascular physiology and in anti-neoplastic
actions [41,49,68] (Fig. 1).
Other signaling pathways
AMPK is an energy sensing molecule that is also activated by
EGCG in hepatocytes, adipocytes, cancer cells, and endothelial cells.
AMPK contributes to inhibition of gluconeogenesis, stimulation of
lipolysis, apoptosis, and reduction of endothelin-1 expression,
respectively (Fig. 3) [15,38,74,85,90]. This activity may contribute to
improvement of insulin sensitivity and vasodilation [12,37,41]. In fact,
EGCG plays an important role in lipid metabolism by regulating
lipolytic and lypogenic enzymes [12,62]. EGCG inhibits fatty acid
synthase (FAS), PPAR gamma, and C/EBP. Fatty acid binding protein 4
(FABP4) and FAS are reduced by upregulation of nuclear beta-catenin
[58]. Knock-down of beta-catenin attenuates inhibition of intracel-
lular lipid accumulation [58]. Upstream kinases for AMPK include
CaMKKβ and liver kinase B1 (LKB1) that are activated by EGCG
[10,15,75]. The previously mentioned Ca2þ signaling contributes to
stimulation of CaMKKβ in response to EGCG treatment of endothelial
cells [47]. The activation of AMPK is dependent on reactive oxygen
species because catalase and N-acetyl cysteine suppress this action of
EGCG [15,38,74]. This is an example of beneﬁcial pro-oxidant actions
of EGCG. In addition to Ca2þ and cyclic nucleotides, a number of
studies demonstrate that other intracellular signaling pathways are
regulated by EGCG. It is difﬁcult to determine uniﬁed EGCG-
stimulated signal transduction pathways. This seems to be highly
dependent on cell type and EGCG concentrations. For example, EGCG
stimulates Src-family kinases, including Fyn in endothelial cells [49],
while EGCG inhibits concanavalin A-stimulated Src in mesenchymal
stromal cells [123]. The concentrations of EGCG in both studies are in a
Fig. 3. Metabolic and vascular functions of EGCG. A schematic diagram showing the mechanisms for the activation of AMPK by EGCG. AMPK is a key molecule that regulates
enzymes involved with energy metabolism and endothelial functions.
Table 4
Effects of EGCG on transcription factors.
Transcription
factor
Cell type Con. EGCG
(μM)
Inhibition/
Activation
Reference
Sp1 LNCaP 20 Inhibition [91]
NF-κB HSC 20–100 Inhibition [9]
RAW264.7 100 Inhibition [120]
Nrf2 HAEC 2.5 Activation [88]
BAEC 25–100 Activation [115]
AP-1 HSC 20–100 Inhibition [9]
Epidermal
cell
5–20 Inhibition [21]
STAT1 Cardiac
myocyte
100 Inhibition [109]
STAT3 A549,
HPAEpiC
10 Inhibition [59]
FOXO1 3T3-L1 100 Inhibition [45,46]
BAEC 10 Inhibition [90]
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similar range (10–50 μM). Ca2þ signaling and Src activation is not
observed in NIH-3T3 ﬁbroblast cells (unpublished observation).
Furthermore, EGCG-stimulated Fyn/PI 3-kinase/Akt/eNOS pathway
contributes to vasorelaxation and protection from ischemia reperfu-
sion injury of cardiac tissues. However, this does not seem to be
mediated through a 67LR-dependent mechanism [49,87]. Puzzlingly, a
similar pathway in cancer cells is mediated by 67LR and leads to
apoptosis [55]. It is conceivable that opposing actions of EGCG may
have differential effects depending onwhether they are integrated into
normal physiology or intervene in dysregulated pathophysiology.
Nuclear function
Cellular responses in intracellular signal transduction pathways
generally occur acutely. However, chronic cellular responses often
involve nuclear functions that regulate gene expression and
chromosomal modiﬁcations. In this section, we will discuss the
effects of EGCG in nuclear function.
Regulation of transcription factors
EGCG modulates gene expression by inhibiting various tran-
scription factors including Sp1, NF-κB, AP-1, STAT1, STAT3 and
FOXO1 (Table 4) [2,9,21,46,59,90,91,109,120]. NF-κB and AP-1
expression are inhibited by EGCG in rats exposed to ischemia-
reperfusion (I/R) injury [4]. EGCG inhibits STAT-1 to mediate
protective effects of EGCG in myocardial I/R injury [104,109].
Multiple studies show that nuclear activities of EGCG inhibit
inﬂammatory responses that are usually accompanied by
increased oxidative stress [6,86]. Thus, one may claim that this
anti-inﬂammatory action is mainly due to direct anti-oxidant
activity of EGCG. However, it is not clear whether anti-oxidative
effects of EGCG are a major mechanism for anti-inﬂammatory
actions of EGCG. Interestingly, EGCG-stimulated production of ROS
that causes activation of NF-κB and NF-E2-related factor 2 (Nrf2)
leading to increased expression of HO-1 and glutathione [88,115].
Scavenging ROS by using various anti-oxidants abolishes EGCG-
stimulated induction of HO-1 while pretreatment with EGCG has
protective effects against hydrogen peroxide-induced cytotoxicity
[115]. It is noteworthy that most in vitro studies use high
concentrations of EGCG to elicit inhibitory actions on transcription
factors. However, in vivo studies may not achieve the concentra-
tions of EGCG used with in vitro studies. These potential differ-
ences in conditions and concentrations of EGCG need to be
carefully considered when interpreting results of experiments
designed to reveal mechanisms for the physiological actions of
EGCG in vivo. Protective mechanisms that EGCG uses to defend
against oxidative stress may be secondary to induction of various
endogenous anti-oxidant proteins. Inhibition of the transcription
factor FOXO1 by EGCG leads to suppression of basal levels of
endothelin-1 (ET-1) and differentiation of adipocytes [45,46]. Both
of these mechanisms are linked to activation of Akt that inhibits
FOXO1 by direct phosphorylation of FOXO1 and may have cardi-
ometabolic implications [56,80].
DNA methylation
EGCG has epigenetic functions in chromosomes [25]. Aberrant
methylation on CpG islands cause gene silencing that leads to
altered cellular physiology and cell proliferation. EGCG inhibits
DNA methyltransferase (DNMT) which reverses methylation-
induced gene silencing by directly binding to DNMT with an IC50
of less than 1 μM EGCG [26]. This suggests that EGCG is trans-
ported to the nucleus. Although this function of EGCG has been
known for a decade, the speciﬁc genes affected by this mechanism
are not well deﬁned and this area requires further investigation.
Mitochondrial function
Mitochondria are organelles that play important roles in energy
production. EGCG intake reduces obesity and expression of leptin
and stearyl-coA desaturase in white adipose cells while increasing fat
oxidation [52]. This suggests that EGCG actions enhance mitochon-
drial fat utilization and reduce adipogenesis in fat tissue. EGCG
stimulates mitochondrial biogenesis and promotes oxidative phos-
phorylation through a cAMP/PKA- and sirtuin-dependent mechan-
ism [111]. With respect to anti-tumor activity, EGCG promotes
apoptosis through mitochondrial damage, membrane depolarization,
and cytochrome c release [89]. This apoptotic action of EGCG is
inhibited by NAC or catalase suggesting that excess hydrogen
peroxide may contribute to mitochondrial damage-induced cell
death. By contrast, the metabolic function of EGCG with regard to
mitochondrial function occurs with much lower concentrations of
EGCG. In some animal models, EGCG enhances mitochondrial func-
tion that reduces oxidative stress in alcoholic fatty liver or diet-
induced obesity [42,52]. In addition, pretreatment with EGCG
(30 mg/kg) protects against mitochondrial damage in isoproterenol-
induced cardiac toxicity in albino Wistar rats [20]. A study using rat
cerebellar granule neurons shows 490% of [3H]–EGCG is found in
the mitochondrial fraction. Moreover, pre-incubation with EGCG
protects against mitochondrial damage-caused cell death without
changes in SOD, glutathione peroxidase, Nrf2, or Bcl2 expression and
oxidative stress. However, toxin-, serum withdrawal-, and protea-
some inhibitor-induced cell death are not prevented by EGCG [100].
This effect of EGCG may be considered a direct anti-oxidant property
of EGCG. However, it is not completely clear if these effects are due to
direct anti-oxidant effects of EGCG alone or additional secondary
molecular interactions including changes in mitochondrial transcrip-
tion activity. These issues require further clariﬁcation with speciﬁc
experiments designed to test well-deﬁned hypotheses.
Autophagy
Autophagy is a lysosomal catabolic process that degrades
accumulated and unnecessary intracellular materials [17,18,69].
Autophagy requires a number of molecules that interact in a
highly organized manner to help determine cell survival or death.
Most polyphenols, including EGCG, resveratrol, quercetin, and
curcumin induce autophagy. This may contribute to anti-aging
effects of polyphenols [84]. Anti-aging actions of polyphenols
mimic effects of calorie restriction [84]. Some studies show that
high concentrations of EGCG (100 μM) inhibit autophagy leading
to apoptosis in macrophage cell lines (Raw 264.7 cells) and cancer
cells [31,124]. By contrast, low concentrations of EGCG (10 μM)
induces autophagy that facilitates degradation of endotoxin-
induced aggregation of high mobility group B-1 (HMGB1) leading
to anti-inﬂammatory actions [65]. We recently reported that EGCG
(10 μM) stimulates autophagy and autophagic ﬂux in endothelial
cells that helps degradation of lipid droplets through a Ca2þ/
CaMKKβ/AMPK dependent mechanism [47]. This may be an
additional mechanism for protective effects of EGCG related to
inﬂammation, lipotoxicity, and cell death. Thus, the regulation of
autophagy by EGCG is dependent on concentration, stress condi-
tions, and cell types. Further studies elucidating more detailed
mechanisms for EGCG or other polyphenols to regulate cell
survival, death, and metabolism will shed light on potential novel
roles for EGCG in promoting health and preventing chronic
diseases characterized by inﬂammation and oxidative stress.
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Summary and perspectives
In this review, we emphasize biological actions of EGCG that do
not directly involve anti-oxidant properties (graphic summary).
EGCG directly interacts with plasma membrane proteins and
phospholipids which stimulates intracellular signaling pathways.
In addition, EGCG is transported to intracellular compartments,
cytosol, mitochondria, lysosome, and nucleus where it mediates
additional biological actions. These various effects are dependent
on cell type, stress conditions, and concentrations of EGCG. Two
major points should be emphasized: one is that the EGCG effects
observed in vitro may not be the same as in vivo. The major reason
for this is that EGCG is readily modiﬁed after absorption through
the gut which modulates bioavailability. Moreover, the concentra-
tions of EGCG often used in in vitro experiments cannot be reached
in vivo in either plasma or tissues in whole animals. Despite these
caveats, we can extend some in vitro results to in vivo physiology.
With moderate and low concentrations of EGCG, low level oxida-
tive stress may be a beneﬁcial cue for the body to initiate
induction of protective anti-oxidant systems and boost immune
responses. Thus, under pathological conditions with increased
oxidative stress (e.g., ischemia/reperfusion, alcoholic fatty liver,
and obesity-induced inﬂammation), supplementation of green tea
polyphenol may help cope with these stressful conditions. A
second important point is that EGCG has cell type- and environ-
ment- speciﬁc responses because gene expression and signaling
molecules are differentially regulated. One prominent action of
EGCG recently discovered is to increase lipolysis through
autophagy-dependent and -independent mechanisms [12,47,62].
This suggests that EGCG plays an important role in lipid metabo-
lism in whole body physiology as well as at the cellular level. In
the future, it will be helpful to identify more speciﬁc biomarkers
that respond to physiologically effective concentrations of EGCG so
that pharmacodynamic studies may be performed with physiolo-
gical outcomes. Further investigations are required to understand
how EGCG acts differentially in different cell types. Recent mole-
cular, cellular, and animal studies have begun to reveal detailed
mechanisms linking drinking green tea and life-style adjustment
with prevention of chronic diseases including cancer, diabetes, and
cardiovascular disorders. Furthermore, chemical modiﬁcation of
an EGCG pharmacophore may modify relative therapeutic activ-
ities so that combinatorial supplementation may synergistically
enhance beneﬁcial health effects [8,30].
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